Loading...
Clinical practice guidelines for the management of adult diffuse gliomas
Зохиогч
Jiang, Tao
Nam, Do-Hyun
Ram, Zvi
Poon, Wai-Sang
Wang, Jiguang
Mao, Ying
Ma, Wenbin
Mao, Qing
You, Yongping
Jiang, Chuanlu
Yang, Xuejun
Kang, Chunsheng
Qiu, Xiaoguang
Li, Wenbin
Li, Shaowu
Chen, Ling
Li, Xuejun
Liu, Zhixiong
Wang, Weimin
Bai, Hongmin
Yao, Yu
Li, Shouwei
Wu, Anhua
Sai, Ke
Li, Guilin
Yao, Kun
Wei, Xinting
Liu, Xianzhi
Zhang, Zhiwen
Dai, Yiwu
Lv, Shengqing
Wang, Liang
Lin, Zhixiong
Dong, Jun
Xu, Guozheng
Ma, Xiaodong
Zhang, Wei
Zhang, Chuanbao
Chen, Baoshi
You, Gan
Wang, Yongzhi
Wang, Yinyan
Bao, Zhaoshi
Yang, Pei
Fan, Xing
Liu, Xing
Zhao, Zheng
Wang, Zheng
Li, Yiming
Wang, Zhiliang
Li, Guanzhang
Fang, Shengyu
Li, Lianwang
Liu, Yanwei
Liu, Shuai
Shan, Xia
Liu, Yuqing
Chai, Ruichao
Hu, Huimin
Chen, Jing
Yan, Wei
Cai, Jinquan
Wang, Hongjun
Chen, Lingchao
Yang, Yuan
Wang, Yu
Han, Lei
Wang, Qixue
Chinese Glioma Cooperative Group (CGCG)
Society for Neuro‐Oncology of China (SNO-China)
Chinese Brain Cancer Association (CBCA)
Chinese Glioma Genome Atlas (CGGA)
Asian Glioma Genome Atlas (AGGA) network
Он
2021 оны хоёрдугаар сар
Төрөл
journal article
Journal
Cancer letters
Volume
499
Start Page
60
End Page
72
ISSN
1872-7980
Хураангуй
To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.
